RxDoctor Payments Data

Leah Velick

Family · Mayfield Heights, OHNPI 1093174633

Payments from drug & device makers

$3,366in general payments, 2019–2025

Across 178 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$555
  • Boehringer Ingelheim$441
  • Novartis$342
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$257
  • Sanofi$248
  • AOP Health US, LLC$157
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$3,366100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,366 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$22,852
Medicare patients
210
Services billed
284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,876$2,203,337
XareltoRivaroxaban467$550,510
JardianceEmpagliflozin155$203,878
Repatha SureclickEvolocumab173$193,706
EntrestoSacubitril/Valsartan121$168,085
BrilintaTicagrelor82$55,550
Dofetilide202$41,461
FarxigaDapagliflozin Propanediol36$37,668
Praluent PenAlirocumab39$28,329
Metoprolol Succinate1,401$19,819
Rosuvastatin Calcium1,028$16,806
Flecainide Acetate398$16,592
Atorvastatin Calcium1,462$15,410
Ezetimibe478$11,959
Ranolazine ErRanolazine88$11,292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$88$2,203,3371,876 claims
Johnson & JohnsonXarelto$66$550,510467 claims
Boehringer IngelheimJardiance, Pradaxa$441$208,894170 claims
NovartisEntresto$342$168,085121 claims
AstraZenecaBrilinta, Farxiga$136$93,218118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.

Other family in Mayfield Heights

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →